Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?
Interstitial lung disease (ILD) is a severe and frequent manifestation of connective tissue diseases (CTD). Due to its debilitating potential, it requires serious evaluation and treatment. The prevalence of ILD in systemic lupus erythematosus (SLE) is still controversial. Therefore, in order to esta...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/11/9388 |
| _version_ | 1797597429895266304 |
|---|---|
| author | Patricia Richter Anca Cardoneanu Nicoleta Dima Ioana Bratoiu Ciprian Rezus Alexandra Maria Burlui Damiana Costin Luana Andreea Macovei Elena Rezus |
| author_facet | Patricia Richter Anca Cardoneanu Nicoleta Dima Ioana Bratoiu Ciprian Rezus Alexandra Maria Burlui Damiana Costin Luana Andreea Macovei Elena Rezus |
| author_sort | Patricia Richter |
| collection | DOAJ |
| description | Interstitial lung disease (ILD) is a severe and frequent manifestation of connective tissue diseases (CTD). Due to its debilitating potential, it requires serious evaluation and treatment. The prevalence of ILD in systemic lupus erythematosus (SLE) is still controversial. Therefore, in order to establish the diagnosis of ILD, an overlap syndrome must be excluded. Increasing the identification of SLE-associated ILD cases should become a target. To treat this complication, various therapies are now being proposed. To date, no placebo-controlled studies were conducted. Regarding another CTD, systemic sclerosis (SSc), SSc-associated ILD is considered one of the leading causes of mortality. The incidence of ILD varies among disease subtypes, being influenced by diagnostic method, but also by disease duration. Due to the high prevalence of this complication, all SSc patients should be investigated for ILD at the time of SSc diagnosis and during the course of the disease. Fortunately, progress was made in terms of treatment. Nintedanib, a tyrosine kinases inhibitor, showed promising results. It appeared to decrease the rate of progression of ILD compared to placebo. This review aimed to provide up-to-date findings related to SLE-associated ILD and SSc-associated ILD, in order to raise awareness of their diagnosis and management. |
| first_indexed | 2024-03-11T03:05:58Z |
| format | Article |
| id | doaj.art-bad60421375d49e4bae2b476cd7ccff5 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T03:05:58Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-bad60421375d49e4bae2b476cd7ccff52023-11-18T07:58:22ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-05-012411938810.3390/ijms24119388Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?Patricia Richter0Anca Cardoneanu1Nicoleta Dima2Ioana Bratoiu3Ciprian Rezus4Alexandra Maria Burlui5Damiana Costin6Luana Andreea Macovei7Elena Rezus8Department of Rheumatology, “Grigore T Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Rheumatology, “Grigore T Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Internal Medicine, “Grigore T Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Rheumatology, “Grigore T Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Internal Medicine, “Grigore T Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Rheumatology, “Grigore T Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Rheumatology, “Grigore T Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Rheumatology, “Grigore T Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaDepartment of Rheumatology, “Grigore T Popa” University of Medicine and Pharmacy, 700115 Iasi, RomaniaInterstitial lung disease (ILD) is a severe and frequent manifestation of connective tissue diseases (CTD). Due to its debilitating potential, it requires serious evaluation and treatment. The prevalence of ILD in systemic lupus erythematosus (SLE) is still controversial. Therefore, in order to establish the diagnosis of ILD, an overlap syndrome must be excluded. Increasing the identification of SLE-associated ILD cases should become a target. To treat this complication, various therapies are now being proposed. To date, no placebo-controlled studies were conducted. Regarding another CTD, systemic sclerosis (SSc), SSc-associated ILD is considered one of the leading causes of mortality. The incidence of ILD varies among disease subtypes, being influenced by diagnostic method, but also by disease duration. Due to the high prevalence of this complication, all SSc patients should be investigated for ILD at the time of SSc diagnosis and during the course of the disease. Fortunately, progress was made in terms of treatment. Nintedanib, a tyrosine kinases inhibitor, showed promising results. It appeared to decrease the rate of progression of ILD compared to placebo. This review aimed to provide up-to-date findings related to SLE-associated ILD and SSc-associated ILD, in order to raise awareness of their diagnosis and management.https://www.mdpi.com/1422-0067/24/11/9388systemic lupus erythematosussystemic sclerosisnintedanibinterstitial lung disease |
| spellingShingle | Patricia Richter Anca Cardoneanu Nicoleta Dima Ioana Bratoiu Ciprian Rezus Alexandra Maria Burlui Damiana Costin Luana Andreea Macovei Elena Rezus Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge? International Journal of Molecular Sciences systemic lupus erythematosus systemic sclerosis nintedanib interstitial lung disease |
| title | Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge? |
| title_full | Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge? |
| title_fullStr | Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge? |
| title_full_unstemmed | Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge? |
| title_short | Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge? |
| title_sort | interstitial lung disease in systemic lupus erythematosus and systemic sclerosis how can we manage the challenge |
| topic | systemic lupus erythematosus systemic sclerosis nintedanib interstitial lung disease |
| url | https://www.mdpi.com/1422-0067/24/11/9388 |
| work_keys_str_mv | AT patriciarichter interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge AT ancacardoneanu interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge AT nicoletadima interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge AT ioanabratoiu interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge AT ciprianrezus interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge AT alexandramariaburlui interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge AT damianacostin interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge AT luanaandreeamacovei interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge AT elenarezus interstitiallungdiseaseinsystemiclupuserythematosusandsystemicsclerosishowcanwemanagethechallenge |